研究者詳細

顔写真

タケイ　ケンタロウ
武井　健太郎
Kentarou Takei
所属
病院　内科　総合感染症科
職名
助教
学位

  • 医学（博士） （東北大学）

所属学協会 3

  • 日本感染症学会感染症専門医

    2023年1月 ～ 継続中

  • 日本内科学会総合内科専門医

    2018年12月 ～ 継続中

  • 日本神経学会神経内科専門医

    2017年7月 ～ 継続中

研究キーワード 1

  • ライフサイエンス

論文 20

  1. High-risk clonal expansion of IMP-producing Enterobacter cloacae complex in regional Japanese healthcare settings 査読有り

    Kentarou Takei, Hajime Kanamori, Ryuji Sakata, Miho Ogawa, Hiroaki Baba, Yumiko Takei, Asami Nakayama, Tetsuji Aoyagi

    Antimicrobial Agents and Chemotherapy　2025年10月17日

    出版者・発行元： American Society for Microbiology

    DOI： 10.1128/aac.00953-25 　

    ISSN：0066-4804

    eISSN：1098-6596

    詳細を見る 詳細を閉じる

    ABSTRACT Carbapenemase-producing Enterobacter cloacae complex (CPEC) represents an emerging threat in healthcare settings; however, its spread across local and regional hospitals remains elusive. Between 2014 and 2022, 211 non-duplicate E. cloacae complex isolates (ECC) with reduced carbapenem susceptibility based on automated susceptibility testing were collected from 58 hospitals in 14 prefectures across Japan. PCR detected the bla IMP-1 group in 92.9% of isolates. Among these, 80 representative CPEC isolates underwent whole-genome sequencing. Two dominant high-risk clonal groups, ST78 and ST133 (including single-locus variants), accounted for 62.5% of sequenced isolates. Notably, ST133—rarely reported in Japan—was the second most common type and detected widely, suggesting gradual and inconspicuous dissemination. ST78 exhibited substantial genomic diversity, frequent co-carriage of extended-spectrum beta-lactamase genes, and multiple plasmid replicons, while ST133 formed a more uniform lineage with limited resistance determinants. Most isolates remained highly susceptible to amikacin and cefiderocol. Core-genome multi-locus sequence typing suggested possible intra-facility persistence and inter-facility transmission of closely related strains (≤10 allele differences) in some hospitals over time. Among the 46 facilities with bla IMP-1 group-positive isolates, 73.9% (34/46) were small hospitals (<200 beds). The proportion among screened ECC isolates was similarly high in small and large hospitals (90.5% vs 94.8%), with no significant difference, suggesting the need to extend molecular surveillance even in resource-limited settings. These findings highlight the utility of molecular confirmation and targeted genomic analysis, particularly in regions or settings where high-risk CPEC clones may circulate undetected, to support timely detection and containment efforts.

  2. Enhanced Effect of Patient Room Disinfection Against Carbapenem-Resistant Enterobacter cloacae and Methicillin-Resistant Staphylococcus aureus Using UV-C Irradiation in Conjunction with UV-C Containment Unit. 国際誌

    Shiori Kitaya, Kentarou Takei, Yoshitomo Honda, Risako Kakuta, Hajime Kanamori

    Antibiotics (Basel, Switzerland)　13　(12)　2024年11月22日

    DOI： 10.3390/antibiotics13121115 　

    詳細を見る 詳細を閉じる

    Background/Objectives: In environments with high-frequency contact surfaces, drug-resistant bacteria, such as carbapenem-resistant Enterobacterales and methicillin-resistant Staphylococcus aureus (MRSA), can survive for extended periods, contributing to healthcare-associated infections. Ultraviolet (UV)-C irradiation often fails to adequately disinfect shadowed areas, leading to a persistent contamination risk. We evaluated the effectiveness of using a UV-C containment unit (UVCCU) in conjunction with UV-C irradiation to improve the sterilization effects on both direct and indirect surfaces, including shadowed areas, and to assess the leakage of UV radiation to the surroundings. Methods: In a model patient room, agar media inoculated with carbapenem-resistant Enterobacter cloacae and MRSA were placed at multiple locations on direct and indirect surfaces around the bed. We used the UV-C irradiation system, UVDI-360, to irradiate the bedroom-environment surfaces with and without a UVCCU. The reduction in bacterial colony counts with and without the UVCCU was measured by counting colony-forming units and calculating the log reduction values, and the UV radiation leakage outside the UVCCU was measured. Results: The use of the UVCCU led to a significant reduction in MRSA colony counts, even in shadowed areas that had previously been inadequately disinfected (with the UVCCU: 2.7 [2.7-2.8]; without the UVCCU: 0.6 [0.5-0.7]; p < 0.01). Additionally, the use of the UVCCU kept the UV radiation leakage to the surrounding environment within regulated limits. Conclusions: These findings suggest that a UVCCU can enhance the disinfection efficacy for multidrug-resistant organisms on healthcare environmental surfaces. The portability and ease of use of the UVCCU indicate its promise as an auxiliary device for UV-C disinfection in healthcare settings.

  3. Molecular Epidemiology of Carbapenem-Resistant Klebsiella aerogenes in Japan. 国際誌 査読有り

    Kentarou Takei, Miho Ogawa, Ryuji Sakata, Hajime Kanamori

    International journal of molecular sciences　25　(8)　2024年4月19日

    DOI： 10.3390/ijms25084494 　

    詳細を見る 詳細を閉じる

    Information regarding Klebsiella aerogenes haboring carbapenemase in Japan is limited. A comprehensive nationwide survey was conducted from September 2014 to December 2022, and 67 non-duplicate strains of carbapenem-resistant K. aerogenes were isolated from 57 healthcare facilities in Japan. Through genetic testing and whole-genome sequencing, six strains were found to possess carbapenemases, including imipenemase (IMP)-1, IMP-6, New Delhi metallo-β-lactamase (NDM)-1, and NDM-5. The strain harboring blaNDM-5 was the novel strain ST709, which belongs to the clonal complex of the predominant ST4 in China. The novel integron containing blaIMP-1 featured the oxacillinase-101 gene, which is a previously unreported structure, with an IncN4 plasmid type. However, integrons found in the strains possessing blaIMP-6, which were the most commonly identified, matched those reported domestically in Klebsiella pneumoniae, suggesting the prevalence of identical integrons. Transposons containing blaNDM are similar or identical to the transposon structure of K. aerogenes harboring blaNDM-5 previously reported in Japan, suggesting that the same type of transposon could have been transmitted to K. aerogenes in Japan. This investigation analyzed mobile genetic elements, such as integrons and transposons, to understand the spread of carbapenemases, highlighting the growing challenge of carbapenem-resistant Enterobacterales in Japan and underscoring the critical need for ongoing surveillance to control these pathogens.

  4. Epidemiological Characteristics of Carbapenem-Resistant Enterobacterales in Japan: A Nationwide Analysis of Data from a Clinical Laboratory Center (2016–2022) 査読有り

    Kentarou Takei, Miho Ogawa, Ryuji Sakata, Hajime Kanamori

    Pathogens　12　(10)　1246-1246　2023年10月16日

    出版者・発行元： MDPI AG

    DOI： 10.3390/pathogens12101246 　

    eISSN：2076-0817

    詳細を見る 詳細を閉じる

    In Japan, nationwide epidemiological surveys on carbapenem-resistant Enterobacterales (CREs), including comprehensive information, are scarce, with most data available only through public reports. This study analyzed data on the Enterobacterales family collected from nationwide testing centers between January 2016 and December 2022, focusing on isolates that met the criteria for CRE in Japan based on drug susceptibility. We investigated 5,323,875 Enterobacterales isolates of 12 different species; among 4696 (0.09%) CRE strains, the proportion of major CRE isolates was as follows: Escherichia coli, 31.3%; Klebsiella pneumoniae, 28.0%; Enterobacter cloacae, 18.5%; and Klebsiella aerogenes, 6.7%. Moreover, over a 7-year period, Providencia rettgeri, E. cloacae, K. aerogenes, and K. pneumoniae demonstrated relatively high CRE percentages of 0.6% (156/26,185), 0.47% (869/184,221), 0.28% (313/110,371), and 0.17% (1314/780,958), respectively. The number of CRE strains isolated from different samples was as follows: urine, 2390; respiratory specimens, 1254; stool, 425; blood, 252; others, 375. In the broader context, including colonization, the predominant isolates of CREs collected at nationwide testing centers are E. coli and K. pneumoniae. Furthermore, recently, attention has been directed toward less common CRE species, such as Klebsiella oxytoca and Providencia rettgeri, and thus, it might be necessary to continue monitoring these less common species.

  5. Severe pneumonia due to Legionella and SARS-CoV-2 co-infection necessitating medical evacuation from a cargo ship. 国際誌

    Shiori Kitaya, Hiroaki Baba, Michiko Okamoto, Masahiro Sakamoto, Asami Nakayama, Yumiko Takei, Issei Seike, Kentarou Takei, Kengo Oshima, Koichi Tokuda, Takuya Shiga, Hajime Kanamori

    Journal of travel medicine　30　(5)　2023年9月5日

    DOI： 10.1093/jtm/taad067 　

  6. Screening for Metallo-Beta-Lactamases Using Non-Carbapenem Agents: Effective Detection of MBL-Producing Enterobacterales and Differentiation of Carbapenem-Resistant Enterobacterales. 国際誌 査読有り

    Kentarou Takei, Hajime Kanamori, Asami Nakayama, Mikiko Chiba, Yumiko Takei, Issei Seike, Chiho Kitamura, Hiroaki Baba, Kengo Oshima, Koichi Tokuda

    Antibiotics (Basel, Switzerland)　12　(7)　2023年7月3日

    DOI： 10.3390/antibiotics12071146 　

    詳細を見る 詳細を閉じる

    Metallo-beta-lactamases (MBLs) are enzymes that break down carbapenem antibiotics, leading to carbapenem-resistant organisms. Carbapenemase-resistant Enterobacterales (CRE) is one of them. Outbreaks of CRE infection can occur in healthcare facilities and lead to increased deaths, illness, and medical costs. This study was conducted to detect MBLs using non-carbapenem agents and exclude MBLs among CRE isolates. A total of 3776 non-duplicate sequential Enterobacterales isolates from a single facility were screened between January 2019 and December 2022 using non-carbapenem agents, ceftazidime and cefoperazone/sulbactam. Positive 153 isolates (4.0%) were further tested using carbapenemase-confirmation tests and verified through polymerase chain reaction (PCR) testing. Fifteen imipenemase (IMP)-type MBL-producing Enterobacterales (0.4%) including one susceptible to carbapenems were identified. Moreover, 160 isolates (4.2%) meeting the criteria for CRE were directly subjected to PCR testing. All fourteen CRE isolates with MBLs identified through PCR testing were found to be the same strains screened using ceftazidime and cefoperazone/sulbactam. Screening using ceftazidime and cefoperazone/sulbactam can effectively detect MBL-producing Enterobacterales strains. This screening method showed comparable results to screening with meropenem, potentially serving as a supplementary approach and contributing to differentiating between MBL- and non-MBL-producing CRE strains. Our findings support these screening methods, particularly in regions where IMP-type MBLs are prevalent.

  7. Circulating Extracellular Vesicle Levels in Patients with Coronavirus Disease 2019 Coagulopathy: A Prospective Cohort Study. 国際誌

    Yudai Iwasaki, Yusuke Takei, Mitsuhiro Yamada, Shigekazu Sugino, Koji Saito, Tetsuji Aoyagi, Kengo Oshima, Hajime Kanamori, Hiroaki Baba, Kentarou Takei, Koichi Tokuda, Eichi N Kodama, Tetsuro Kamo, Tadashi Kamio, Takehiko Kasai, Satoru Ogawa, Masanori Yamauchi

    Journal of clinical medicine　12　(10)　2023年5月14日

    DOI： 10.3390/jcm12103460 　

    詳細を見る 詳細を閉じる

    Coronavirus disease 2019 (COVID-19) is associated with coagulopathy. However, the underlying mechanisms are not completely understood. We evaluated the association between COVID-19 coagulopathy and extracellular vesicle (EV) levels. We hypothesized that several EV levels would be higher in COVID-19 coagulopathy patients than in non-coagulopathy patients. This prospective observational study was conducted in four tertiary care faculties in Japan. We enrolled 99 COVID-19 patients (48 with coagulopathy and 51 without coagulopathy) aged ≥20 years who required hospitalization, and 10 healthy volunteers; we divided the patients into coagulopathy and non-coagulopathy groups according to the D-dimer levels (≥1 μg/mL and <1 μg/mL, respectively). We used flow cytometry to measure the tissue-factor-bearing, endothelium-derived, platelet-derived, monocyte-derived, and neutrophil-derived EV levels in platelet-free plasma. The EV levels were compared between the two COVID-19 groups as well as among the coagulopathy patients, non-coagulopathy patients, and healthy volunteers. No significant difference was found in EV levels between the two groups. Meanwhile, the cluster of differentiation (CD) 41 + EV levels were significantly higher in COVID-19 coagulopathy patients than in healthy volunteers (549.90 [255.05-984.65] vs. 184.3 [150.1-254.1] counts/µL, p = 0.011). Therefore, CD41+ EVs might play an essential role in COVID-19 coagulopathy development.

  8. Clinical and Epidemiological Characteristics of Persistent Bacteremia: A Decadal Observational Study. 国際誌

    Shiori Kitaya, Hajime Kanamori, Hiroaki Baba, Kengo Oshima, Kentarou Takei, Issei Seike, Makoto Katsumi, Yukio Katori, Koichi Tokuda

    Pathogens (Basel, Switzerland)　12　(2)　2023年1月29日

    DOI： 10.3390/pathogens12020212 　

    詳細を見る 詳細を閉じる

    Background: Bloodstream infections (BSIs), including persistent bacteremia (PB), are a leading source of morbidity and mortality globally. PB has a higher mortality rate than non- PB, but the clinical aspects of PB in terms of the causative pathogens and the presence of clearance of PB are not well elucidated. Therefore, this study aimed to describe the clinical and epidemiological characteristics of PB in a real-world clinical setting. Methods: We performed a retrospective observational survey of patients who underwent blood culture between January 2012 and December 2021 at Tohoku University Hospital. Cases of PB were divided into three groups depending on the causative pathogen: gram-positive cocci (GPC), gram-negative rods (GNRs), and Candida spp. For each group, we examined the clinical and epidemiological characteristics of PB, including differences in clinical features depending on the clearance of PB. The main outcome variable was mortality, assessed as early (30-day), late (30-90 day), and 90-day mortality. Results: Overall, we identified 31,591 cases of single bacteremia; in 6709 (21.2%) cases, the first blood culture was positive, and in 3124 (46.6%) cases, a follow-up blood culture (FUBC) was performed. Of the cases with FUBCs, 414 (13.2%) were confirmed to be PB. The proportion of PB cases caused by Candida spp. was significantly higher (29.6%, 67/226 episodes) than that for GPC (11.1%, 220/1974 episodes, p < 0.001) and GNRs (12.1%, 100/824 episodes, p < 0.001). The Candida spp. group also had the highest late (30-90 day) and 90-day mortality rates. In all three pathogen groups, the subgroup without the clearance of PB tended to have a higher mortality rate than the subgroup with clearance. Conclusions: Patients with PB due to Candida spp. have a higher late (30-90 day) and 90-day mortality rate than patients with PB due to GPC or GNRs. In patients with PB, FUBCs and confirming the clearance of PB are useful to improve the survival rate.

  9. Emphysematous gastritis due to hypervirulent Klebsiella pneumoniae. 国際誌

    Naomi Saeki, Kentaro Takei, Ken Katsuta, Akihiko Nakasato, Hiroaki Baba, Kengo Oshima, Koichi Tokuda, Shigeki Kushimoto, Hajime Kanamori

    The Lancet. Infectious diseases　22　(11)　1648-1648　2022年11月

    DOI： 10.1016/S1473-3099(22)00545-X 　

  10. Severe coronavirus disease 2019 in a patient with TAFRO syndrome: A case report. 国際誌

    Kengo Oshima, Hajime Kanamori, Kentarou Takei, Hiroaki Baba, Koichi Tokuda

    Clinical infection in practice　16　100158-100158　2022年11月

    DOI： 10.1016/j.clinpr.2022.100158 　

    詳細を見る 詳細を閉じる

    BACKGROUND: TAFRO syndrome, a subtype of idiopathic multicentric Castleman disease, is an acute or subacute systemic inflammatory disease that causes fever, generalized oedema (pleural effusion or ascites), and thrombocytopenia and is associated with renal impairment, anaemia, and organomegaly (hepatosplenomegaly and lymph node enlargement). Coronavirus disease 2019 (COVID-19)-associated hyperinflammation is caused by dysregulation of proinflammatory cytokines. Cytokine storm syndrome is common to both COVID-19 and TAFRO syndrome.Case report.A 66-year-old man with TAFRO syndrome was admitted because of worsening renal function, right pleural effusion, and ascites. He was taking 20 mg prednisolone orally and 25 mg cyclosporin A orally twice daily. Despite administration of maximum oxygenation and remdesivir, the patient developed acute respiratory distress syndrome (ARDS) and was transferred to the intensive care unit. RESULTS: Chest radiography showed bilateral lung infiltration. COVID-19 was confirmed with a positive polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2. Chest and abdominal computed tomography showed massive ground-glass opacities in both lungs, slight right pleural effusion, hepatomegaly, splenomegaly, and ascites. CONCLUSION: To the best of our knowledge, this is the first report of COVID-19 in a patient with TAFRO syndrome. Despite receiving a moderate dose of a corticosteroid and a monoclonal antibody against the IL-6 receptor, our patient developed severe pneumonia, suggesting that strong immunomodulatory therapy in the antiviral phase of COVID-19 may promote viral growth and induce ARDS.

  11. Clinical features of COVID-19 patients with rebound phenomenon after corticosteroid therapy

    Koji Murakami, Hirohito Sano, Naoki Tode, Yoko Tsukita, Kei Sato, Daisuke Narita, Nozomu Kimura, Shuichiro Matsumoto, Yoshinao Ono, Chikashi Iwasaki, Hatsumi Sugiyama, Manami Suzuki, Sho Kakuto, Shuichi Konno, Hajime Kanamori, Hiroaki Baba, Kengo Oshima, Kentarou Takei, Koichi Tokuda, Tsutomu Tamada, Hisatoshi Sugiura

    BMJ OPEN RESPIRATORY RESEARCH　9　(1)　2022年9月

    DOI： 10.1136/bmjresp-2022-001332 　

    eISSN：2052-4439

  12. Multiple Secondary Healthcare-Associated Infections Due to Carbapenem-Resistant Organisms in a Critically Ill COVID-19 Patient on Extensively Prolonged Venovenous Extracorporeal Membrane Oxygenation Support-A Case Report. 国際誌

    Hiroaki Baba, Hajime Kanamori, Issei Seike, Ikumi Niitsuma-Sugaya, Kentaro Takei, Kengo Oshima, Yudai Iwasaki, Yuko Ogata, Hirona Nishimaki, Daisuke Konno, Takuya Shiga, Koji Saito, Koichi Tokuda, Tetsuji Aoyagi

    Microorganisms　10　(1)　2021年12月23日

    DOI： 10.3390/microorganisms10010019 　

    詳細を見る 詳細を閉じる

    Patients with severe Coronavirus disease 2019 (COVID-19) are at high risk for secondary infection with multidrug-resistant organisms (MDROs). Secondary infections contribute to a more severe clinical course and longer intensive care unit (ICU) stays in patients with COVID-19. A man in his 60s was admitted to the ICU at a university hospital for severe COVID-19 pneumonia requiring mechanical ventilation. His respiratory condition worsened further due to persistent bacteremia caused by imipenem-non-susceptible Klebsiella aerogenes and he required VV-ECMO. Subsequently, he developed a catheter-related bloodstream infection (CRBSI) due to Candida albicans, ventilator-associated pneumonia (VAP) due to multidrug-resistant Pseudomonas aeruginosa (MDRP), and a perianal abscess due to carbapenem-resistant K. aerogenes despite infection control procedures that maximized contact precautions and the absence of MDRO contamination in the patient's room environment. He was decannulated from VV-ECMO after a total of 72 days of ECMO support, and was eventually weaned off ventilator support and discharged from the ICU on day 138. This case highlights the challenges of preventing, diagnosing, and treating multidrug-resistant organisms and healthcare-associated infections (HAIs) in the critical care management of severe COVID-19. In addition to the stringent implementation of infection prevention measures, a high index of suspicion and a careful evaluation of HAIs are required in such patients.

  13. Disseminated gonococcal infection in a patient with paroxysmal nocturnal haemoglobinuria receiving eculizumab. 国際誌

    Ikumi Niitsuma-Sugaya, Hajime Kanamori, Satoshi Ichikawa, Noriko Fukuhara, Issei Seike, Kentaro Takei, Hiroaki Baba, Kengo Oshima, Tetsuji Aoyagi, Hideo Harigae, Koichi Tokuda

    The Lancet. Infectious diseases　21　(5)　741-741　2021年5月

    DOI： 10.1016/S1473-3099(20)30930-0 　

  14. Case Report: Successful Treatment of Five Critically Ill Coronavirus Disease 2019 Patients Using Combination Therapy With Etoposide and Corticosteroids. 国際誌

    Tetsuji Aoyagi, Yukio Sato, Hiroaki Baba, Takuya Shiga, Issei Seike, Ikumi Niitsuma Sugaya, Kentarou Takei, Yudai Iwasaki, Kengo Oshima, Hajime Kanamori, Makiko Yoshida, Koji Saito, Koichi Tokuda, Mitsuo Kaku

    Frontiers in medicine　8　718641-718641　2021年

    DOI： 10.3389/fmed.2021.718641 　

    詳細を見る 詳細を閉じる

    Acute respiratory distress syndrome (ARDS) is the leading cause of mortality in hospitalized patients with coronavirus disease 2019 (COVID-19) because of limited effective therapies. During infection, the accumulation and activation of macrophages and monocytes in the lungs induce inflammatory mediators and contribute to tissue injury, leading to ARDS. However, therapeutic strategies that directly target activated macrophage and monocytes have not been reported. Combination treatment with etoposide (a cytotoxic agent) and a corticosteroid has been widely used for treating hemophagocytic lymphohistiocytosis characterized by the systemic activation of macrophages with overwhelming inflammation. Herein, we present five cases of COVID-19-associated ARDS treated with etoposide and corticosteroids. Three of the five patients were over 65 years of age and had various underlying diseases, including multiple myeloma. Four patients required invasive mechanical ventilation (MV), and one patient refused to be placed on MV due to underlying diseases. All patients were pre-treated with antiviral and/or other anti-inflammatory agents, but their condition deteriorated and hyperinflammation was noted. All five patients responded well to treatment and had an immediate response, as reflected by improvement in their respiratory condition and inflammatory marker levels and rapid resolution of fever after etoposide administration; however, some patients required a second dose of etoposide and longer course of steroids. All patients recovered, and there were no severe adverse events related to the drugs. Following successful treatment in these five patients, we plan to conduct a clinical trial to evaluate the efficacy and safety of combination therapy with etoposide and corticosteroid for treating COVID-19 patients in Japan.

  15. Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid arthritis taking iguratimod treated with ciclesonide. 国際誌

    Hiroaki Baba, Hajime Kanamori, Kengo Oshima, Issei Seike, Ikumi Niitsuma-Sugaya, Kentaro Takei, Yukio Sato, Koichi Tokuda, Tetsuji Aoyagi

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy　26　(10)　1100-1103　2020年10月

    DOI： 10.1016/j.jiac.2020.06.022 　

    詳細を見る 詳細を閉じる

    We report a coronavirus disease 2019 (COVID-19) case with rheumatoid arthritis taking iguratimod. The patient who continued iguratimod therapy without dose reduction was treated with ciclesonide had an uneventful clinical course, but prolonged detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was observed after resolution of symptoms. The effects of disease-modifying antirheumatic drugs (DMARDs) and ciclesonide on clinical course and viral shedding remain unknown and warrant further investigation.

  16. Marchiafava-Bignami disease with haemophagocytic lymphohistiocytosis as a postoperative complication of cardiac surgery. 国際誌 査読有り

    Kentarou Takei, Naotaka Motoyoshi, Kazuhiro Sakamoto, Tetsuyuki Kitamoto

    BMJ case reports　12　(8)　2019年8月26日

    DOI： 10.1136/bcr-2019-230368 　

    詳細を見る 詳細を閉じる

    Marchiafava-Bignami disease (MBD) is a rare complication of chronic alcoholism; however, MBD in a non-alcoholic diabetic patient has rarely been reported. The aetiology or pathophysiology of MBD is still unknown. A 50-year-old man with a history of untreated diabetes mellitus underwent on-pump beating coronary artery bypass graft surgery (CABG) surgery for three-vessel and left main coronary disease. 3 days after the surgery, he developed a fever over 40°C and entered a coma state. MRI revealed multiple lesions, including in the corpus callosum, globus pallidus, brain stem and upper cervical spinal cord, which suggested MBD. The patient did not respond to thiamine therapy, but partly responded to steroid therapy. He ultimately died of respiratory failure. The autopsy revealed MBD and haemophagocytic lymphohistiocytosis. It is rare, but systemic inflammatory response syndrome induced by on-pump beating CABG could develop these complication.

  17. An Acute Case of Granulomatous Amoebic Encephalitis-Balamuthia mandrillaris Infection. 査読有り

    Kentarou Takei, Masaya Toyoshima, Masashi Nakamura, Mineshige Sato, Hiroshi Shimizu, Chihiro Inoue, Yoshio Shimizu, Kenji Yagita

    Internal medicine (Tokyo, Japan)　57　(9)　1313-1316　2018年5月1日

    DOI： 10.2169/internalmedicine.0011-17 　

    詳細を見る 詳細を閉じる

    A 74-year-old woman who exhibited drowsiness was referred to our hospital. Enhanced head magnetic resonance imaging (MRI) revealed multiple ring-enhancing lesions and lesions showing partial mild hemorrhaging. The patient gradually progressed to a comatose condition with notable brain deterioration of unknown cause on follow-up MRI. On day nine, the patient inexplicably died, although brain herniation was suspected. Autopsy and histopathology revealed numerous amoebic trophozoites in the perivascular spaces and within the necrotic tissue. Brain immunostaining tested positive for Balamuthia mandrillaris. Infection due to free-living amoeba is rare in Japan; however, it may increase in the near future due to unknown reasons.

  18. Fingolimod-associated PML with mild IRIS in MS: A clinicopathologic study. 国際誌

    Shuhei Nishiyama, Tatsuro Misu, Yukiko Shishido-Hara, Kazuo Nakamichi, Masayuki Saijo, Yoshiki Takai, Kentarou Takei, Naoki Yamamoto, Hiroshi Kuroda, Ryuta Saito, Mika Watanabe, Teiji Tominaga, Ichiro Nakashima, Kazuo Fujihara, Masashi Aoki

    Neurology(R) neuroimmunology & neuroinflammation　5　(1)　e415　2018年1月

    DOI： 10.1212/NXI.0000000000000415 　

    詳細を見る 詳細を閉じる

    OBJECTIVE: To clarify the clinical, neuropathologic, and virologic characteristics of progressive multifocal leukoencephalopathy (PML) and its immune reconstitution inflammatory syndrome (IRIS) in a patient with fingolimod-treated MS. METHODS: A case study. RESULTS: A 34-year-old patient with MS using fingolimod for 4 years had a gradual progression of right hemiparesis and aphasia with a new subcortical white matter lesion in the precentral gyrus by initial MRI. Blood tests were normal, except for lymphopenia (160 cells/μL). One month after the cessation of fingolimod, brain MRI depicted a diffusely exacerbated hyperintensity on fluid-attenuated inversion recovery and diffusion-weighed imaging in the white matter with punctate gadolinium enhancement, suggesting PML-IRIS. A very low level of JC virus (JCV)-DNA (15 copies/mL) was detected in the CSF as judged by quantitative PCR. Brain tissues were biopsied from the left frontal lesion, which showed some small demyelinated foci with predominant loss of myelin-associated glycoprotein with infiltrations of lymphocytes and macrophages, but clear viral inclusion was not observed with hematoxylin-eosin staining. JCV-DNA was uniquely detectable in an active inflammatory demyelinating lesion by in situ hybridization, possibly suggesting an early phase of PML. DNA extracted from the brain sample was positive for JCV-DNA (151 copies/cell). It took 3 months to normalize the blood lymphocyte count. The patient was treated with 1 g of IV methylprednisolone for 3 days and a weekly oral dose (375 mg) of mefloquine, and her symptoms gradually improved. CONCLUSION: Low CSF JCV-DNA and unfound viral inclusions initially made her diagnosis difficult. The clinical course of fingolimod-associated PML may be associated with mild immune reconstitution.

  19. Case of anti-myelin oligodendrocyte glycoprotein antibody-associated demyelinating disease with atopic dermatitis 査読有り

    Kentarou Takei, Mineshige Sato, Masashi Nakamura, Hiroshi Shimizu, Ichiro Nakashima

    Clinical and Experimental Neuroimmunology　8　(2)　138-140　2017年5月1日

    出版者・発行元： Wiley-Blackwell

    DOI： 10.1111/cen3.12365 　

    ISSN：1759-1961

  20. Longitudinally extensive transverse myelitis with anti-NMDA receptor antibodies during a systemic lupus erythematosus flare-up. 国際誌 査読有り

    Kentarou Takei, Mineshige Sato, Masashi Nakamura, Hiroshi Shimizu

    BMJ case reports　2015　2015年11月26日

    DOI： 10.1136/bcr-2015-212112 　

    詳細を見る 詳細を閉じる

    Transverse myelitis (TM) with systemic lupus erythematosus (SLE) has been linked to the presence of autoantibodies (eg, antiaquaporin 4 (AQP4) and anticardiolipin (aCL)) and SLE-induced secondary vasculitis, but the aetiology remains incompletely understood. A 48-year-old Japanese man with a 6-year history of poorly controlled SLE had stopped glucocorticoid therapy 1 year before admission. 3 days before admission, he developed flaccid paraplegia. Spinal MRI showed a longitudinally hyperintense T2 grey matter lesion from the level of Th4 to the conus medullaris, which was considered longitudinally extensive TM (LETM). We administered steroid pulse therapy (methyl-prednisolone 1000 mg/day) for 3 days and prednisolone 50 mg/day. The patient's flaccid paralysis gradually improved. We concluded that the patient's TM was caused by SLE flare-up, even though we could not completely rule out antiphospholipid syndrome. SLE myelitis is relatively rare and many aetiologies are possible for TM in SLE.

︎全件表示 ︎最初の5件までを表示

MISC 43

  1. 広範な病変を呈した播種性皮膚Mycobacterium chelonae感染症の1例

    大藪 公平, 馬場 啓聡, 粟田 潤, 清家 一生, 北村 知穂, 武井 健太郎, 中山 麻美, 大島 謙吾, 青柳 哲史

    感染症学雑誌　100　(1)　98-98　2026年1月

    出版者・発行元： (一社)日本感染症学会

    ISSN： 0387-5911

    eISSN： 1884-569X

  2. カンボジア渡航歴のある日本人男性に発症したセフタジジム耐性Burkholderia pseudomalleiによる類鼻疽の1例

    東北大学病院, 総合感染症科, 吉田美智子, 馬場啓聡, 大島謙吾, 武井健太郎, 清家一生, 青柳哲史, 心臓血管外科, 齋木佳克, 熊谷紀一郎, 高橋悟朗, 伊藤校輝, 板垣皓大, 工藤 淳, 微生物検査室, 千葉美紀子, 感染管理室, 北村知穂, 遠藤春樹, 石戸谷真帆, 池田しのぶ, 仙台市保健所, 荒井由美子

    感染症発生動向調査月報（IASR）　46　209-210　2025年10月

  3. 抗菌治療を受けた患者由来Candida parapsilosisにおけるアゾール耐性メカニズム(Azole Resistance Mechanisms in Candida parapsilosis From a Patient Receiving Antifungal Therapy)

    Sarah Craveiro Martins, 新居 鉄平, 青柳 哲史, 渡邉 哲, 武井 健太郎, 本田 芳宏

    日本医真菌学会雑誌　66　(Suppl.1)　98-98　2025年9月

    出版者・発行元： (一社)日本医真菌学会

    ISSN： 2434-5229

    eISSN： 2434-5237

  4. 抗HIV治療により寛解に至ったAIDS合併潰瘍性大腸炎の一例

    粟田 潤, 馬場 啓聡, 清家 一生, 中山 麻美, 北村 知穂, 武井 健太郎, 大島 謙吾, 青柳 哲史

    日本感染症学会総会・学術講演会・日本化学療法学会学術集会合同学会プログラム・抄録集　99回・73回　O-252　2025年4月

    出版者・発行元： 日本感染症学会・日本化学療法学会

  5. 抗真菌療法を受けている患者から分離された汎アゾール耐性Candida parapsilosisにおけるアゾール耐性の機序【JST機械翻訳】|||

    SARAH Craveiro Martins, 新居鉄平, 武井健太郎, 本田芳宏, 青柳哲史, 青柳哲史, 渡辺哲

    関東医真菌懇話会プログラム・抄録集　44th　2025年

    ISSN： 2433-6874

  6. Tsukamurella conjunctivitisにより引き起こされたカテーテル関連血流感染症の一例

    北谷 栞, 金森 肇, 北村 知穂, 武井 健太郎, 馬場 啓聡, 大島 謙吾, 青柳 哲史

    日本臨床微生物学会雑誌　35　(Suppl.1)　348-348　2024年12月

    出版者・発行元： (一社)日本臨床微生物学会

    ISSN： 2434-866X

  7. UV-C紫外線照射装置のカルバペネム耐性腸内細菌目細菌の環境除菌効果およびUVC コンテインメントユニットの有用性についての検討

    武井 健太郎, 角田 梨紗子, 本多 功知, 金森 肇

    第232回 日本内科学会 東北地方会　2024年6月22日

  8. コロナ禍における20代女性の不明熱の1症例

    北村 知穂, 馬場 啓聡, 武井 健太郎, 清家 一生, 金森 肇, 大島 謙吾, 徳田 浩一, 青柳 哲史

    第231回 日本内科学会 東北地方会　2024年2月17日

  9. 患者さんからよく尋ねられる内科診療のQuestion 第6章 感染症[28歳女性,既往歴なし]毎回風邪をひくと抗生物質を飲まないと治らないので,出してもらえますか?

    武井健太郎, 青柳哲史

    内科　133　(4)　2024年

    ISSN： 0022-1961

  10. 新型コロナウイルスとLegionella pneumophilaの共感染による重症肺炎で太平洋上の貨物船から医療搬送された一例

    北谷 栞, 馬場 啓聡, 大島 謙吾, 武井 健太郎, 清家 一生, 徳田 浩一, 中山 麻美, 金森 肇

    日本感染症学会総会・学術講演会・日本化学療法学会学術集会合同学会プログラム・抄録集　97回・71回　O-143　2023年3月

    出版者・発行元： 日本感染症学会・日本化学療法学会

  11. 東北大学病院における持続的菌血症の検討

    北谷 栞, 金森 肇, 大島 謙吾, 馬場 啓聡, 武井 健太郎, 清家 一生, 勝見 真琴, 徳田 浩一

    日本感染症学会総会・学術講演会・日本化学療法学会学術集会合同学会プログラム・抄録集　97回・71回　O-087　2023年3月

    出版者・発行元： 日本感染症学会・日本化学療法学会

  12. HSVによる肝炎発症後,産褥期にElsberg症候群を発症した一症例

    北村 知穂, 武井 健太郎, 清家 一生, 馬場 啓聡, 金森 肇, 大島 謙吾, 徳田 浩一

    日本感染症学会総会・学術講演会・日本化学療法学会学術集会合同学会プログラム・抄録集　97回・71回　O-181　2023年3月

    出版者・発行元： 日本感染症学会・日本化学療法学会

  13. COVID-19に対するステロイド治療後再燃例の検討

    村上 康司, 佐野 寛仁, 東出 直樹, 佐藤 慶, 徳田 浩一, 大島 謙吾, 金森 肇, 馬場 啓聡, 武井 健太郎, 玉田 勉, 杉浦 久敏

    日本呼吸器学会誌　11　(増刊)　212-212　2022年4月

    出版者・発行元： (一社)日本呼吸器学会

    ISSN： 2186-5876

    eISSN： 2186-5884

  14. 担癌患者および自己免疫疾患患者における緑膿菌による前立腺膿瘍の2例

    清家 一生, 金森 肇, 武井 健太郎, 新妻 郁未, 馬場 啓聡, 大島 謙吾, 徳田 浩一, 青柳 哲史

    感染症学雑誌　95　(臨増)　217-217　2021年4月

    出版者・発行元： (一社)日本感染症学会

    ISSN： 0387-5911

    eISSN： 1884-569X

  15. Rhodotorula mucilaginosaによるカテーテル関連血流感染症の1例

    佐藤 裕真, 金森 肇, 清家 一生, 新妻 郁未, 武井 健太郎, 馬場 啓聡, 大島 謙吾, 徳田 浩一, 青柳 哲史

    感染症学雑誌　95　(臨増)　218-218　2021年4月

    出版者・発行元： (一社)日本感染症学会

    ISSN： 0387-5911

    eISSN： 1884-569X

  16. Good症候群に伴うサイトメガロウイルス網膜炎の一例

    武井 健太郎, 金森 肇, 清家 一生, 新妻 郁未, 馬場 啓聡, 大島 謙吾, 徳田 浩一, 青柳 哲史

    感染症学雑誌　95　(臨増)　225-225　2021年4月

    出版者・発行元： (一社)日本感染症学会

    ISSN： 0387-5911

    eISSN： 1884-569X

  17. 発熱と皮疹を主訴としたCOVID-19の2例

    清家 一生, 金森 肇, 馬場 啓聡, 新妻 郁未, 武井 健太郎, 大島 謙吾, 徳田 浩一, 青柳 哲史

    感染症学雑誌　95　(臨増)　259-259　2021年4月

    出版者・発行元： (一社)日本感染症学会

    ISSN： 0387-5911

    eISSN： 1884-569X

  18. エクリズマブ投与患者における播種性淋菌感染症の1例

    新妻 郁未, 金森 肇, 清家 一生, 武井 健太郎, 馬場 啓聡, 大島 謙吾, 青柳 哲史, 徳田 浩一

    感染症学雑誌　95　(臨増)　289-289　2021年4月

    出版者・発行元： (一社)日本感染症学会

    ISSN： 0387-5911

    eISSN： 1884-569X

  19. Good症候群に伴うサイトメガロウイルス網膜炎の一例

    武井健太郎, 金森肇, 金森肇, 金森肇, 清家一生, 新妻郁未, 馬場啓聡, 馬場啓聡, 大島謙吾, 大島謙吾, 徳田浩一, 徳田浩一, 徳田浩一, 青柳哲史, 青柳哲史, 青柳哲史

    日本化学療法学会雑誌　69　(Supplement-A)　2021年

    ISSN： 1340-7007

  20. 発熱と皮疹を主訴としたCOVID-19の2例

    清家一生, 金森肇, 金森肇, 金森肇, 馬場啓聡, 馬場啓聡, 新妻郁未, 武井健太郎, 大島謙吾, 大島謙吾, 徳田浩一, 徳田浩一, 徳田浩一, 青柳哲史, 青柳哲史

    日本化学療法学会雑誌　69　(Supplement-A)　2021年

    ISSN： 1340-7007

  21. Rhodotorula mucilaginosaによるカテーテル関連血流感染症の1例

    佐藤裕真, 佐藤裕真, 金森肇, 清家一生, 新妻郁未, 武井健太郎, 馬場啓聡, 大島謙吾, 徳田浩一, 青柳哲史

    日本化学療法学会雑誌　69　(Supplement-A)　2021年

    ISSN： 1340-7007

  22. エクリズマブ投与患者における播種性淋菌感染症の1例

    新妻郁未, 金森肇, 金森肇, 金森肇, 清家一生, 武井健太郎, 馬場啓聡, 馬場啓聡, 大島謙吾, 大島謙吾, 青柳哲史, 青柳哲史, 徳田浩一, 徳田浩一, 徳田浩一

    日本化学療法学会雑誌　69　(Supplement-A)　2021年

    ISSN： 1340-7007

  23. 経過中に心刺激伝導系異常を呈したCOVID-19感染症の2症例

    武井健太郎, 馬場, 啓聡, 金森, 肇 大島, 謙吾, 清家, 一生, 菅谷, 新妻, 郁未 徳田, 浩一, 青柳 哲史

    新型コロナ肺炎（COVID-19）の緊急症例報告（日本感染症学会）　2020年5月

  24. 急性頸髄硬膜外血腫の臨床的特徴

    佐藤 一輝, 黒澤 和大, 此松 和俊, 武井 健太郎, 清水 洋

    臨床神経学　59　(Suppl.)　S262-S262　2019年11月

    出版者・発行元： (一社)日本神経学会

    ISSN： 0009-918X

    eISSN： 1882-0654

  25. New-onset refractory status epilepticusの両側前障病変に関する脳MRIと病態の検討

    黒澤 和大, 此松 和俊, 佐藤 一輝, 武井 健太郎, 高橋 幸利, 清水 洋

    臨床神経学　59　(Suppl.)　S307-S307　2019年11月

    出版者・発行元： (一社)日本神経学会

    ISSN： 0009-918X

    eISSN： 1882-0654

  26. 可逆性後部白質脳症症候群における拡散強調画像とArterial Spin Labelingの有用性

    此松 和俊, 黒澤 和大, 佐藤 一輝, 武井 健太郎, 清水 洋

    臨床神経学　59　(Suppl.)　S344-S344　2019年11月

    出版者・発行元： (一社)日本神経学会

    ISSN： 0009-918X

    eISSN： 1882-0654

  27. 超急性期脳梗塞との鑑別を要した片麻痺の1例

    佐藤 一輝, 此松 和俊, 武井 健太郎, 黒澤 和大, 清水 洋

    臨床神経学　59　(7)　475-475　2019年7月

    出版者・発行元： (一社)日本神経学会

    ISSN： 0009-918X

    eISSN： 1882-0654

  28. 両側視床病変を呈した脳静脈洞血栓症の一例

    張替 宗介, 武井 健太郎, 黒澤 和大, 清水 洋

    臨床神経学　58　(8)　534-534　2018年8月

    出版者・発行元： (一社)日本神経学会

    ISSN： 0009-918X

    eISSN： 1882-0654

  29. Fingolimod-Associated PML with Mild Immune Reconstitution Inflammatory Syndrome in Multiple Sclerosis

    Shuhei Nishiyama, Tatsuro Misu, Yukiko Shishido-Hara, Kazuo Nakamichi, Masayuki Saijo, Yoshiki Takai, Kentarou Takei, Naoki Yamamoto, Hiroshi Kuroda, Ryuta Saito, Mika Watanabe, Teiji Tominaga, Ichiro Nakashima, Kazuo Fujihara, Masashi Aoki

    MULTIPLE SCLEROSIS JOURNAL　24　(3)　381-382　2018年3月

    ISSN： 1352-4585

    eISSN： 1477-0970

  30. 当院レベチラセタム単剤治療症例におけるトラフ血中濃度測定の発作管理に対する有用性の検討

    清水洋, 黒澤和大, 武井健太郎, 此松和俊, 佐藤一輝

    てんかん研究　36　(2)　2018年

    ISSN： 0912-0890

  31. 肉芽腫性アメーバ性脳炎の1例

    豊嶋 昌弥, 黒澤 和大, 中村 正史, 清水 洋, 坂元 和宏, 武井 健太郎

    臨床神経学　57　(6)　354-354　2017年6月

    出版者・発行元： (一社)日本神経学会

    ISSN： 0009-918X

    eISSN： 1882-0654

  32. Prolonged exercise testにより診断した低カリウム性周期性四肢麻痺の一例

    武井 健太郎, 小野 理佐子, 中村 貴彬, 西山 修平, 黒田 宙, 長谷川 隆文, 青木 正志

    臨床神経学　56　(11)　810-810　2016年11月

    出版者・発行元： (一社)日本神経学会

    ISSN： 0009-918X

    eISSN： 1882-0654

  33. アトピー性皮膚炎の増悪を機に発症した抗MOG抗体関連脱髄疾患の1例

    武井 健太郎, 佐藤 峰成, 中村 正史, 清水 洋, 中島 一郎

    神経免疫学　21　(1)　140-140　2016年9月

    出版者・発行元： (一社)日本神経免疫学会

    ISSN： 0918-936X

  34. 頸椎硬膜外血腫の1例

    豊嶋 昌弥, 佐藤 峰成, 武井 健太郎, 中村 正史, 清水 洋

    臨床神経学　56　(8)　586-586　2016年8月

    出版者・発行元： (一社)日本神経学会

    ISSN： 0009-918X

    eISSN： 1882-0654

  35. 下肢の筋痛で発症し呼吸困難で発覚した小児のギラン・バレー症候群の1例

    太田裕也, 宮野峻輔, 阿部雄紀, 和田陽一, 有馬正貴, 鳴海僚彦, 工藤充哉, 武井健太郎, 清水洋, 植松有里佳

    日本小児科学会雑誌　120　(10)　2016年

    ISSN： 0001-6543

  36. Prolonged exercise testにより診断した低カリウム性周期性四肢麻痺の一例

    武井健太郎, 小野理佐子, 中村貴彬, 西山修平, 黒田宙, 長谷川隆文, 青木正志

    臨床神経学(Web)　56　(11)　2016年

    ISSN： 1882-0654

  37. 頚椎硬膜外血腫の1例

    豊嶋昌弥, 佐藤峰成, 武井健太郎, 中村正史, 清水洋

    臨床神経学(Web)　56　(8)　2016年

    ISSN： 1882-0654

  38. SLE再燃に伴うLongitudinal extensive transverse myelitisの一例

    武井 健太郎, 佐藤 峰成, 中村 正史, 清水 洋

    臨床神経学　55　(7)　512-512　2015年7月

    出版者・発行元： (一社)日本神経学会

    ISSN： 0009-918X

    eISSN： 1882-0654

  39. 当院におけるMPO-ANCA関連腎炎の初期治療ガイドラインと1年生命予後の関連

    武井 健太郎, 滝沢 英毅, 嶋村 昌之介, 茂庭 仁人, 長谷川 浩一, 田中 繁道, 小川 弥生, 浦 信行

    日本腎臓学会誌　57　(3)　485-485　2015年4月

    出版者・発行元： (一社)日本腎臓学会

    ISSN： 0385-2385

    eISSN： 1884-0728

  40. 今インフルエンザシーズンの初めに経験したA(H1)pdm09亜型ウイルスによる健康成人の重症インフルエンザ肺炎症例について―札幌

    手稲渓仁会病院, 武井健太郎, 水戸陽貴, 岸田直樹, 芹澤良幹, 国立病院機構仙台医療センター臨床研究部ウイルスセンター, 伊藤洋子, 大宮, 卓 西村秀一

    感染症発生動向調査月報（IASR）　35　(2)　41-42　2014年2月

  41. Panton-Valentine leucocidin(PVL)陽性MRSAによる難治性慢性中耳炎の一例

    武井 健太郎, 矢野 寿一, 平潟 洋一, 新井 和明, 金森 肇, 遠藤 史郎, 石橋 令臣, 青柳 哲史, 八田 益充, 西巻 雄司, 山田 充啓, 徳田 浩一, 北川 美穂, 阿部 裕子, 長沢 光章, 國島 広之, 賀来 満夫

    感染症学雑誌　85　(臨増)　312-312　2011年3月

    出版者・発行元： (一社)日本感染症学会

    ISSN： 0387-5911

    eISSN： 1884-569X

  42. 不飽和土と凍土における空気-氷-水分布の類似性

    武井健太郎, 庄司浩通, 鞠谷佳郎, 森淳子, 赤川敏

    地盤工学研究発表会発表講演集　39th　2004年

    ISSN： 1342-2863

  43. 土の鉱物組成と比表面積および不凍水分量の関係

    鞠谷佳郎, 武井健太郎, 原口征人, 赤川敏

    地盤工学会北海道支部技術報告集　(43)　2003年

︎全件表示 ︎最初の5件までを表示